1. Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
2. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye;Behar Cohen F. F.;Investigative Ophthalmology & Visual Science,1996
3. A Novel Nitric Oxide Releasing Prostaglandin Analog, NCX 125, Reduces Intraocular Pressure in Rabbit, Dog, and Primate Models of Glaucoma
4. Safety and efficacy of latanoprostene bunod 0.024% ophthalmic solution (vyzultaTM) in normal and glaucomatous dogs with ADAMTS10‐open angle glaucoma (ADAMTS10‐OAG) preliminary findings;Burn J. B.;2020 ACVO Proceedings ACVO 51st Annual Conference,2020
5. Nitric oxide (NO): An emerging target for the treatment of glaucoma;Cavet M. E.;Investigative Ophthalmology & Visual Science,2014